Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1095 of 6351
-
Brittle bone breakthrough? new drug combo aims to cut fractures
Disease control CompletedOsteogenesis imperfecta (OI) is an inherited skeletal disorder characterised by increased risk of fragility fractures. Bisphosphonates are frequently prescribed for adult patients with OI with the aim of preventing fractures but the evidence base for efficacy is poor. Recent evid…
Phase 4 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a cholesterol drug boost reading skills in kids with NF1?
Disease control OngoingNeurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memor…
Phase 2 • Sponsor: Vanderbilt University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New study uses MRI to catch pancreatic cancer early in High-Risk families
Diagnosis Recruiting nowThe main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to …
Sponsor: Nuvance Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Cold virus engineered to attack pancreatic cancer shows promise in early trial
Disease control CompletedThe purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the…
Phase 1/2 • Sponsor: Lokon Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can taking drug breaks work as well as continuous treatment for melanoma?
Disease control Recruiting nowThe purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of tre…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a new interferon tame hepatitis d?
Disease control CompletedTo evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
Phase 2 • Sponsor: EIT Pharma, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Promising new pill shrinks liver fat in NASH patients
Disease control CompletedThe primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Phase 2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can breathing exercises help ICU patients break free from the ventilator?
Disease control CompletedVentilator-induced diaphragmatic dysfunction appears to contribute to slow weaning from mechanical ventilation. Several trials of inspiratory muscle training to facilitate weaning in intensive care have been performed, with inconsistent results, utilizing different methods of IMT…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for myeloma: experimental drug iberdomide tested in combo therapy
Disease control OngoingThis is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220…
Phase 1/2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Ebola vaccine booster study aims to strengthen protection for frontline workers
Prevention CompletedBackground: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection. A vaccine to prevent infection either before or after exp…
Phase 2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for tough pancreatic cancers
Disease control CompletedThis is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without preoperat…
Phase 2 • Sponsor: Institut de Cancérologie de Lorraine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Supercharged immune cells take on childhood cancers
Disease control OngoingPatients with high-risk solid tumors, those that are refractory to standard up front therapy or relapse after completion of therapy, have a very poor prognosis despite attempts to induce remission with salvage regimen. Novel therapies are critical for this patient population with…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could 10 minutes of daily mindfulness shield children from anxiety?
Prevention OngoingThis study evaluates the short and long-term effect of 5-10 minutes daily mindfulness and compassion training in school among children aged between 6-16 years old. The mindfulness intervention will last for 10 weeks and the results will be compared to children who do not perform …
Sponsor: Lund University • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo may boost stem cell transplant success in hard-to-treat lymphoma
Disease control OngoingThis randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for aggressive breast cancer: targeted combo before surgery
Disease control OngoingThis randomized phase II trial studies how well carboplatin and paclitaxel with or without panitumumab work in treating patients with invasive triple negative breast cancer. Drugs used in the chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the gro…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Custom RNA vaccines take on aggressive breast cancer in first human test
Disease control CompletedThe Mutanome Engineered RNA Immuno-Therapy (MERIT) study introduced a novel concept for Individualized Cancer Immunotherapy (IVAC®) to treat each patient with the relevant and immunogenic RNA vaccines for a given patient's tumor. The TNBC-MERIT trial used two complementary strate…
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can Ice-Cold saline save trauma victims in cardiac arrest?
Disease control Stopped earlyThe goal of this study is to rapidly cool trauma victims who have suffered cardiac arrest from bleeding with a flush of ice-cold sodium chloride to preserve the patient to enable surgical control of bleeding, followed by delayed resuscitation with cardiopulmonary bypass.
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
High-Dose cocktail shows promise against new myeloma
Disease control CompletedThe purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New enzyme combo aims to break down pancreatic tumors
Disease control OngoingThe purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies w…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Zap and delay: radiation may buy time for cancer patients
Disease control OngoingA multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of ol…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC